Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avricore Health (AVCRF) EBITDA (2016 - 2025)

Historic EBITDA for Avricore Health (AVCRF) over the last 17 years, with Q3 2025 value amounting to -$275362.8.

  • Avricore Health's EBITDA fell 10977.75% to -$275362.8 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year decrease of 161939.93%. This contributed to the annual value of -$488654.8 for FY2024, which is 597.67% up from last year.
  • Avricore Health's EBITDA amounted to -$275362.8 in Q3 2025, which was down 10977.75% from -$331765.5 recorded in Q2 2025.
  • In the past 5 years, Avricore Health's EBITDA ranged from a high of $125073.5 in Q1 2024 and a low of -$510055.4 during Q4 2024
  • Its 5-year average for EBITDA is -$110379.9, with a median of -$53871.6 in 2025.
  • As far as peak fluctuations go, Avricore Health's EBITDA surged by 39542.43% in 2023, and later crashed by 126539.99% in 2024.
  • Quarter analysis of 5 years shows Avricore Health's EBITDA stood at -$45013.1 in 2021, then tumbled by 290.68% to -$175856.1 in 2022, then soared by 124.89% to $43766.6 in 2023, then plummeted by 1265.4% to -$510055.4 in 2024, then surged by 46.01% to -$275362.8 in 2025.
  • Its last three reported values are -$275362.8 in Q3 2025, -$331765.5 for Q2 2025, and -$53871.6 during Q1 2025.